Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078321" target="_blank" >RIV/65269705:_____/23:00078321 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00133414 RIV/00216208:11130/23:10467129 RIV/00064203:_____/23:10467129
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/full/10.1111/hae.14847" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1111/hae.14847</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/hae.14847" target="_blank" >10.1111/hae.14847</a>
Alternative languages
Result language
angličtina
Original language name
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres
Original language description
IntroductionHaemophilia A care has changed with the introduction of emicizumab. Experience on the youngest children is still scarce and clinical practice varies between haemophilia treatment centres.AimWe aimed to assess the current clinical practice on emicizumab prophylaxis within PedNet, a collaborative research platform for paediatricians treating children with haemophilia.MethodsAn electronic survey was sent to all PedNet members (n = 32) between October 2022 and February 2023. The survey included questions on the availability of emicizumab, on the practice of initiating prophylaxis in previously untreated or minimally treated patients (PUPs or MTPs) and emicizumab use in patients with or without inhibitors.ResultsAll but four centres (28/32; 88%) responded. Emicizumab was available in clinical practice in 25/28 centres (89%), and in 3/28 for selected patients only (e.g. with inhibitors). Emicizumab was the preferred choice for prophylaxis in PUPs or MTPs in 20/25 centres; most (85%) started emicizumab prophylaxis before 1 year of age (30% before 6 months of age) and without concomitant FVIII (16/20; 80%). After the loading dose, 13/28 centres administered the recommended dosing, while the others adjusted the interval of injections to give whole vials. In inhibitor patients, the use of emicizumab during ITI was common, with low-dose ITI being the preferred protocol.ConclusionMost centres choose to initiate prophylaxis with emicizumab before 12 months of age and without concomitant FVIII. In inhibitor patients, ITI is mostly given in addition to emicizumab, but there was no common practice on how to proceed after successful ITI.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Haemophilia
ISSN
1351-8216
e-ISSN
1365-2516
Volume of the periodical
29
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
1291-1298
UT code for WoS article
001061475100001
EID of the result in the Scopus database
2-s2.0-85169166367